This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty.

Sarepta Therapeutics’ stock has dropped precipitously as questions swirl around the safety of its gene therapies. Meanwhile, ...

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a strategic restructuring and cost-cutting measures. What To Know: After ...

Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug Administration that it could resume shipping a drug it paused sales of last week.

Boston Business Journal By Jess Aloe – Digital Editor, Boston Business Journal Jun 16, 2025 Updated Jun 16, 2025 5:04pm EDT Preview this article 1 min ...

Former institutional trader Kevin Muir flags caution on chasing this market as he sees some big market whales nearing the end of a U.S. stock buying spree.

Sarepta's stock has collapsed this year after two patients taking its Elevidys drug for Duchenne muscular dystrophy died of acute liver failure. Through Wednesday's close, its shares were down 85% ...